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Convenience sample of healthcare providers and the general public were recruited at an
acute care community hospital in Ontario, Canada.
Participants
In the first phase, 63 respondents provided 197 unique viewpoints in response to a topic
statement about medical cannabis use in critically ill patients. Twenty-five viewpoints were
selected for the q-sample. In the second phase, 99 respondents ranked these viewpoints
according to an a priori quasi normal distribution ranging from +4 (most agree) to -4 (least
agree). Factor analysis was combined with comments provided by survey respondents to
label and describe the extracted factors.
Results
The factor labels were hoping and caring (factor 1), pragmatic progress (factor 2), and cau-
tious/conservative and protectionist (factor 3). Factor 1 describes a viewpoint of unequivocal
support for medical cannabis research in this population with few caveats. Factor 2
describes a viewpoint of cautious support with a need to monitor for unintended adverse
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effects. Factor 3 describes a viewpoint of ensuring that current analgosedation techniques
are optimized before exposing patients to another potentially harmful drug.
Conclusions
Using a q-methodology design, we were able to sample and describe the viewpoints that
exist about medical cannabis research in critically ill patients. Three factors emerged that
seemed to adequately describe the relative ranking of q-statements by the majority of
respondents. Combining the distinguishing statements along with respondent comments
allowed us to determine that the majority support medical cannabis research in critically ill
patients.
Introduction
Life-sustaining therapies, such as invasive mechanical ventilation, are commonly employed in
patients admitted to an intensive care unit (ICU) with life-threatening illnesses. The majority
of these patients require pain control and sedation to facilitate their care but also to alleviate
suffering directly related to their illness [1]. Opioids represent the primary pharmacologic
agents used to manage pain and sedation in the ICU. This is referred to as analgosedation,
analgesia-mediated sedation. Ideally, critically ill patients should be exposed to the minimum
doses of opioids that relieves their suffering, facilitates their care, and exposes them to the min-
imum number of both short- and long-term consequences and complications. Unfortunately,
there is no a priori established dose range of opioids that fulfils these requirements for every
patient given the subjective nature of pain and suffering [2]. The current strategies to manage
pain in critically ill patients depend on using validated pain scoring systems and frequent clini-
cal assessment by ICU nurses to guide the titration of opioids and other pharmacologic thera-
pies used for analgosedation [3]. Despite these considerable efforts, many patients still receive
either too little or too much opioids during their ICU admission, either of which may have
many negative consequences for patients. Too little opioids expose patients to unrelieved pain
that may adversely affect their psychological well-being, cause them to resist care provided by
health care providers, put them at risk of self-harm from events such as self-extubation, and
may activate pathologic stress responses resulting in events such as gastrointestinal bleeding or
hypertension. Too much opioids exposes patients to excess days on a ventilator due to respira-
tory depression, altered levels of alertness and severe delirium, and the development of toler-
ance to opioids requiring ever-increasing amounts to manage pain that may lead to the risk of
a withdrawal syndrome and chronic opioid tolerance.
Medical cannabis has been shown to be an effective therapy in treating chronic pain [4].
The evidence for efficacy of medical cannabis use to alleviate other pain syndromes is currently
lacking [5]. There are no clinical trials demonstrating the efficacy of using medical cannabis as
an adjunct to analgosedation as either an opioid-sparing agent or to alleviate the psychological
complications associated with critical illness such as delirium or post-traumatic stress disorder
(PTSD). A recent search of ClinicalTrials.com using the search terms “Medical cannabis”,
“Medical marijuana”, “Medicinal cannabis”, “Marijuana treatment”, and “Medicinal mari-
juana” yielded 167 studies, none of which involved critically ill patients (https://clinicaltrials.
gov/ct2/results/details?term=Medical+cannabis). Despite this lack of evidence, some pre-clini-
cal studies suggest that medical cannabis may have an important role in modulating the
inflammatory response, an important potentiator of both pain and illness severity in critically
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ill patients [6, 7]. In addition, preliminary studies suggest a positive effect of medical cannabis
on PTSD-related symptoms such as nightmares [8]. PTSD is a common long-term conse-
quence of critical illness as part of a syndrome referred to as post-intensive care syndrome
(PICS) that can affect up to 30% to 50% of ICU survivors [9]. These potential benefits of medi-
cal cannabis, along with its recent legalization and lower risk profile compared to opioids [10],
make it a candidate therapy for investigation in critically ill patients at high risk of opioid toler-
ance and PICS.
Apart from the clinical rationale for medical cannabis use in critically ill patients, there
have been no studies exploring the viewpoints of both the public and health care providers on
the potential role of medical cannabis in these patients. To date, almost all cannabis products
approved for medical use demonstrate efficacy in patients with terminal or refractory health
conditions such as chronic cancer pain and epilepsy [4]. Given that there are alternative strate-
gies to analgosedation and the risks from medical cannabis use may not be as benign as previ-
ously believed [11–13], it remains uncertain whether there would be both public and health
care provider support for medical cannabis research in this complex patient population.
Q-methodology is a mixed method study design used to describe different viewpoints that
may exist about any topic [14]. Participants are provided with a topic statement to review. This
statement is rarely neutral as it is intended to elicit divergent and strong opinions. Participants
are then asked to provide their viewpoints in response to this topic statement in 2 different
phases. The first phase involves generating a q-set, a theoretic population of all viewpoints that
may exist. These viewpoints may emerge from many different sources such as journal articles,
expert opinion, popular media or stakeholders. Once collected, a strategic sampling of the q-
set is completed to ensure that all unique and relevant viewpoints are represented in a q-sam-
ple. In the second phase, stakeholders are asked to rank the q-sample statements according to
their agreement using an a priori quasi normal distribution, a q-sort. This relative ranking cre-
ates a unique q-sort pattern for each respondent. In addition to the q-sort, stakeholders are
asked to provide qualitative comments about why they ranked statements in the most agree,
least agree and neutral categories. The q-sorts are then analysed using factor analyses tech-
niques, and only those factors with significant loadings on the q-sorts are retained. These fac-
tors are labelled and described using both distinguishing q-sample statements and the
comments provided by stakeholders. These factors represent latent viewpoints about the topic
of interest.
We designed a q-methodology study to determine if health care providers and the public
would support medical cannabis research in critically ill ventilated patients, and demonstrated
a favourable response from both groups in their support of this research activity.
Materials and methods
The study was approved by the Royal Victoria Regional Health Centre Research Ethics Board
(REB#R18-010) on September 26, 2018. Consent was obtained from each study participant
before entering the survey.
Q-methodology design
We used a q-methodology study design to systematically explore and describe the range of
viewpoints about medical cannabis research in critically ill ventilated patients among relevant
stakeholders [15]. Our study was limited to stakeholders who might be directly affected by the
use of medical cannabis in critically ill patients. The investigators created a topic statement
about the use of medical cannabis in critically ill patients using their content expertise in pain
medicine (SH), naturopathic medicine (KC) and critical care (GD) (S1 Appendix, Topic
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Statement). This topic statement was used in both phases of the q-methodology study. The sur-
vey participants for both phases were sampled from both the lay public and health care provid-
ers located at the Royal Victoria Regional Health Centre in Barrie, Ontario by using a non-
probability strategy. The survey participants were strategically sampled to ensure high poten-
tial for broad, discrepant and extensive sets of viewpoints were represented in the q-set and q-
sample phases. Survey respondents who participated in phase 1 were asked not to participate
in phase 2. Survey participants that had critical care experience and that were critical care-
naïve were sampled from both the lay public and health care provider groups. The usual total
sample size target for q-set development is between 40 to 60 survey participants [15]. All the
statements from phase 1 were reviewed by all three investigators using an informal approach
to finalize the statements that were included in the q-set. This informal approach involved
each of the 3 investigators independently reviewing the entire set of q-set statements. The
investigators independently grouped similar statements into themes, and created q-set state-
ments that were representative of these groupings. Once this was completed, the investigators
independently ranked the q-set statements in order from most relevant/preferred for inclusion
to least relevant/preferred for inclusion. All the investigators attempted to rank and include
the q-set statements in such a way as to ensure their final q-sort statements represented the
most unique and diverse viewpoints. Once the investigators each completed their independent
review of the q-set statements, they convened to review each other’s q-set statements’ rankings.
Through an iterative process, the final q-sort statements were chosen if there was unanimous
agreement among the 3 investigators for inclusion. The investigators also used their own clini-
cal expertise to supplement the final q-sort statements to ensure a sufficiently broad and com-
prehensive set of viewpoints were included in the final q-sort. From this process, a final list of
25 statements was chosen by the investigators to create the q-sample (S1 Appendix in Table 1).
In phase 2, participants ranked these q-sample statements according to their relative agree-
ment or disagreement using a forced distribution (Fig 1), with each survey respondent creating
their own unique q-statement ranking pattern, q-sort. The usual total sample size target for q-
sort is also between 40 to 60 survey participants.
Further qualitative information was requested after the q-sort by asking survey participants
to explain why they had ranked statements at either extreme of the quasi normal distribution,
why they had ranked statements as neutral and their overall viewpoints about the topic state-
ment. Completed q-sorts were analyzed using principal factor analysis, a quantitative data
reduction technique, to identify survey respondents with highly correlated q-sort patterns
[16]. These intercorrelated survey participants were considered to share similar viewpoints
about the topic statement, and these viewpoints are termed factors. Factors represent the
observable viewpoints of latent perspectives. The output from this analysis are ‘idealized’ q-
sorts with characteristic patterns for each factor. Survey participants’ q-sorts were variably
explained by one or a combination of these factors. The extent that each participant’s q-sort is
explained by these factors is termed a factor load. The factors that explain most of the variation
across� 2 q-sorts were retained. The final output of the analysis was a descriptive labelling of
each factor that emerged by combining the q-sorts, along with those statements that distin-
guish one factor from another and was further supported by the qualitative statements pro-
vided by participants at the end of the q-sort.
Data collection and analysis
Both phases of the q-methodology study were programmed in REDCap© (https://www.
project-redcap.org), a Personal Health Information Protection Act-compliant database stored
at the Royal Victoria Regional Health Centre (Access to the q survey phase 1 and phase 2
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templates for review is available upon request). After obtaining Research Ethics Board
approval on September 26, 2018 (REB #R18-010), a link for the phase 1 q-set survey was dis-
tributed to all intensive care unit (ICU) staff email addresses along with a request for participa-
tion. Snowball sampling of other hospital staff was done by asking ICU staff to forward the
request for participation emails along with the survey link to other hospital staff they felt
would be interested in learning more about the study and potentially participating. In addi-
tion, a study brochure explaining the rationale, the research question, the requirements of par-
ticipation and the study survey link was made available to families and patients in the ICU by
the ICU charge nurse during daily inter-disciplinary rounds. In addition, volunteer high
school students approached potential participants in the hospital’s common areas, such as the
Fig 1. Quasi normal distribution used to force ranking of q-statements by participants.
https://doi.org/10.1371/journal.pone.0248475.g001
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cafeteria, to explain the rationale for the study and provide interested participants with a study
brochure to support lay public recruitment. The study brochures were also advertised at all
hospital entrances to support lay public recruitment. Participants were asked to provide
informed consent online prior to participation. The phase 1 q-set survey was open from Octo-
ber 1, 2018 to November 30, 2018 which was defined a priori. Once completed, the investiga-
tors reviewed all the participants’ statements and created a final q-set from which the q-sample
statements were selected. The phase 2 q-sample survey was similarly distributed. The q-sample
survey was open from December 10, 2018 to February 28, 2019. All quantitative analyses were
conducted using the qfactor command in STATA 15/MP [17]. The iterated principal factor
method was used to extract from 2 to 5 factors. Promax oblique rotation was used after factor
extraction for further data reduction and refinement of factor groupings. The regression
method was used to estimate factor z-scores. Distinguishing statements between factors were
identified using a Cohen’s d-value� 0.8. All participants’ comments regarding their rationale
for ranking were reviewed by all three investigators. Using these free-hand comments to sup-
plement the distinguishing factor statements, a final label and description for each of the
retained factors was developed. To label the factors, the investigators identified strongly differ-
entiating statements using the following criteria: those with a� |2| difference in ranking score
from other factors along with having an extreme ranking score value (either +4 or -4 or zero
for neutral). The investigators supplemented these with the supportive qualitative comments
to assist with final factor labelling and description.
Results
In phase 1, there were 105 participants who consented to the survey, with 63 respondents sub-
mitting their viewpoints. The distribution of lay public and health care provider participants
with and without critical care experience was unbalanced (Table 1).
From these 197 unique viewpoints, the investigators created a q-set consisting of 70 state-
ments. From these 70 statements, 25 final viewpoints were sampled to create the q-sample (S1
Appendix in Table 1).
In phase 2, there were 253 participants who consented, with 118 respondents submitting
their q-sorts. After cleaning the database, 99 q-sorts were included in the final analysis as 19
surveys had missing data (Table 2). There was a much more balanced representation across
public and health care provider groups.
For this study, we ultimately extracted 3 factors using the rationale that there were likely to
be 2 groups defined by opposing viewpoints on critical issues, and a third group that was
defined as being either supportive or against depending on the circumstances. The factor
Table 1. Number and distribution of statements among health care providers and the public from phase 1.
Respondent Type1 Respondents (Total number) Age group (Total number) Statements (Total number)
Under 30 30–50 Over 50
HCP ICU+ 47 8 28 11 147
HCP ICU- 11 3 7 1 33
Public ICU+ 2 0 1 1 6
Public ICU- 3 1 0 2 11
Total 63 12 36 15 197
1 HCP ICU+ = any health care provider whose primary clinical care area is the ICU (this could include nurses, physicians, dieticians, physiotherapists, pharmacists,
medical residents, etc.); HCP ICU- = any health care provider whose primary clinical care area is outside the ICU; Public ICU+ = lay public who have family or friends
admitted to the ICU; Public ICU- = lay public who have never had family or friends admitted to the ICU.
https://doi.org/10.1371/journal.pone.0248475.t001
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extraction resulted in 3 factors with their own unique q-sort pattern that serves as the “best-
estimate” or “average” of the statement ranking configuration for that factor (Fig 2).
As seen in Fig 2, the 3 factors have considerable overlapping patterns, differing mostly on
degree of ranking as opposed to having opposing rankings. When one looks at how much of
the variance in q-sort patterns was explained by each factor, Factor 1 accounts for the majority
of the variance (Table 3), with 48 participants’ q-sorts being best described by Factor 1.
Table 2. Number and distribution of completed q-sorts among health care providers and the public from phase 2.
Respondent Type Respondents (Total number) Age group (Total number)
Under 30 30–50 Over 50
HCP ICU+ 31 7 20 4
HCP ICU- 29 5 20 4
Public ICU+ 9 5 4 0
Public ICU- 20 15 4 1
Total 99 32 48 9
https://doi.org/10.1371/journal.pone.0248475.t002
Fig 2. Q-sort patterns of 3 uniquely identified factors.
https://doi.org/10.1371/journal.pone.0248475.g002
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The correlation between factor patterns was low, with all correlation coefficients ranging
from 0.3 to 0.49. Factor loadings reflect correlations between the observed q-sort patterns and
their respective factor patterns, where the (factor loading)2 = variance of the q-sort pattern
attributable to that factor (S1 Appendix in Table 2).
The distribution of factor loadings between the public and health care providers did dem-
onstrate some variability. There were no differences between the distribution of either factor 1
(χ2 (3) = 4.97, p = 0.174) or factor 3 (χ2 (3) = 6.01, p = 0.111), but there was a difference
between these groups for factor 2 (χ2 (3) = 16.89, p = 0.001) with the majority of the public
(both with and without ICU experience) (10/20 participants) being best described by this fac-
tor. There were significant differences in the distribution of factors between different age
groups: factor 1 (χ2 (3) = 23.01, p<0.001), factor 2 (χ2 (3) = 9.32, p = 0.025), and factor 3 (χ2
(3) = 11.29, p = 0.010). The majority of under 30 year olds were best described by factors 2 and
3 (16/32), while factor 1 best described those between 30 and 50 years old (35/48), and those
over 50 years old were best described by both factors 1 and 2.
Distinguishing q-sample viewpoints are those statements that are ranked uniquely for one
factor compared to the others that serve to help label the factor (S1 Appendix in Table 3). In
this study, distinguishing statements were defined as demonstrating differences� 2 between
average factor scores. By this criteria, factor 1 had 6, factor 2 had 3 and factor 3 had 4 distin-
guishing statements.
As opposed to distinguishing statements, there were also consensus q-sample viewpoints.
These elicited similar rankings across all factors (S1 Appendix in Table 4). There were 7 con-
sensus statements.
The final factor labelling was Hoping and Caring (Factor 1), Pragmatic Progress (Factor 2)
and Cautious/Conservative and Protectionist (Factor 3). A description of these factors and an
example of their supporting statements are provided in the supplement (S1 Appendix in
Table 5).
Discussion
The perception of medical cannabis and its use as a medicinal therapy is changing globally as
more countries have legalized recreational marijuana use and liberated prescribing restrictions
for physicians [18, 19]. Even the World Health Organization is reconsidering its policies
around medical cannabis, and is set to vote on rescheduling cannabis from its current Sched-
ule IV classification that restricts its use as a legitimate medical therapeutic [20]. These chang-
ing policies and attitudes have led to an upsurge in cannabis research [21]. It is in this
emerging climate of increasing public and provider acceptance of both recreational and medi-
cal cannabis that we undertook this study to examine the feasibility of studying medical canna-
bis as an adjunct to analgosedation in critically ill patients.
In this study examining viewpoints about cannabis research in critically ill ventilated
patients, we demonstrated that general consensus among sampled health care providers and
the public exists supporting this research activity. By using a q-methodology study design, 3
unique factors were identified that were used to adequately describe the q-sort patterns of
Table 3. Variance in q-sort patterns due to Factors 1, 2 and 3.
Factor Eigenvalue (= Variance) Proportion (of Total Variance) Q-sorts (Total number)
1 47.56 0.81 48
2 6.39 0.11 12
3 4.76 0.08 7
https://doi.org/10.1371/journal.pone.0248475.t003
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more than 67% of the survey participants. The factors described viewpoints that ranged from
being fully supportive of cannabis research without caveats to supporting a cautious research
approach that was limited in scope and patient eligibility. This study is the first to use a q-
methodology approach to elicit viewpoints about cannabis research among stakeholders. Pre-
vious studies have demonstrated varying levels of public and health care provider support for
medical cannabis use that is dependent on many contextual factors that include clinical indica-
tion and knowledge and beliefs about the benefits and harms associated with medical cannabis
use [22–24]. By using this approach, we were able to reduce the complexity of this topic into a
practicable number of shared viewpoints. In addition, the results of the study also provide
guidance on whom to include and exclude in medical cannabis research, what outcomes
should be targeted for impact and who should be involved in the design, financing, conduct
and analysis of the research thus providing a novel technique to include stakeholders in plan-
ning future research studies. For example, at risk populations such as pregnant women, those
with substance abuse disorders or mental health patients were identified as being groups that
should be excluded from inclusion in any subsequent studies due to potential risks associated
with medical cannabis use. Many stakeholders identified that long-term outcomes such as
medical cannabis abuse disorder as a negative consequence of enrolment should also be moni-
tored as a safety signal. In addition, the majority of stakeholders agreed that medical cannabis
producers and companies who are funders of any subsequent studies should be completely
removed from the design, conduct, analyses and reporting of the study results.
The major limitation of the study is the external validity of the results. While we attempted
to create a comprehensive set of viewpoints to be included in the q-sort, there was a statement
imbalance in creating the concourse between the lay public and health care provider groups.
In addition, the method of choosing the final q-statements from the q-set generated in phase
41 of the study was left up to the 3 investigators. While this selection process required agree-
ment between all 3 investigators for final inclusion and all 3 investigators had very different
backgrounds, there may have been some selection bias in choosing the final q-sort statements
that could have affected the final factors that emerged from the study, Having said this, every
q-study is intrinsically limited by the process that must be implemented to choose the final q-
sort statements and our study was consistent in its approach to that used in other q-studies.
However, q methodology is robust to small sample sizes as it doesn’t seek to determine the dis-
tribution of these viewpoints in the population, only the number of different viewpoints that
might exist. Analysis of the distribution of these groups to different factors confirmed that
while there were important differences, these differences were mostly in degree of support for
medical cannabis research as opposed to contrasting opinions (See Description in S1 Appen-
dix in Table 5). In addition, approximately 32% of survey participant’s q-sort patterns were
not described by the 3 factors described in this study, suggesting there may exist significant
heterogeneity of viewpoints beyond those we described. A review of their comments, however,
did not reveal strong viewpoints against supporting cannabis research but rather neutrality
about the subject.
Conclusions
Hoping and caring, pragmatic progress and cautious and protectionist viewpoints emerged as
the three dominant themes among stakeholders. There was significant overlap in these view-
points for their support of research involving the use of medical cannabis as an analgosedative
agent in critically ill ventilated patients. The difference between these viewpoints was in the
degree of support with the hoping and caring unequivocal in their support while the cautious
and protectionist imploring optimization of current therapies before the introduction of
PLOS ONE Public and healthcare provider opinion about cannabis research in critically ill patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0248475 March 18, 2021 9 / 11
another potentially harmful drug. Given this stakeholder input, we belive there is sufficient
support for proceeding with medical cannabis research as an adjunct to analgosedation in crit-
ically ill ventilated patients. The next steps involve planning for a pilot study to investigate the
doses and formulations of enteral medical cannabis that could be safely administered to criti-
cally ill patients while measuring outcomes related to opioid-sparing effects and ameliorating
the incidence and severity of other ICU-related complications such as acute delirium and
PICS.
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